The hunt for better treatments for Huntington's disease

Symptomatic therapies for Huntington's disease do exist and are widely used for treating chorea and some of the psychiatric aspects of the condition, although the extent to which they are effective varies between patients,3 and many patients experience clinically significant side-effects. [...]there is a need to develop better symptomatic therapies, ideally single drugs that can treat more than one sign or symptom. Furthermore, the pathology of Huntington's disease is not limited to the dopaminergic network,9 and the contribution of this wider pathology to the clinical features of the disease is unknown. [...]stabilising dopaminergic function in the brain of patients with Huntington's disease might be of limited value, as suggested by the results of PRIDE-HD. [...]the value of this entire therapeutic approach could be debated given that therapies targeting the motor aspects of Huntington's disease already exist.